Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Roche, Catalent and Novo Nordisk
Roche Comes Out Against Allowing Takeover of Drug Manufacturer Catalent
Last week, U.S. consumer groups and labour unions petitioned the U.S. Federal Trade Commission to block Novo Holdings, the controlling shareholder of Novo Nordisk, from acquiring Catalent, saying the deal threatened competition in weight loss drugs and cutting-edge gene therapies.
Roche CEO says Novo's Catalent buyout 'could be a problem' for smaller drugmakers
The groups behind the letter alleged that Novo Nordisk’s plant purchases could hinder not only the Danish drugmaker’s chief commercial rival, Eli Lilly, but also companies like Viking Therapeutics, Pfizer, Roche and AstraZeneca, who are working on their own metabolic offerings.
Roche CEO says antitrust regulators should block Catalent sale to Novo Holdings (update)
Roche CEO opposes Novo Nordisk's acquisition of Catalent, citing concerns about competition in the pharmaceutical industry.
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
On Wednesday, Roche Holdings AG (OTC:RHHBY) released its third-quarter sales report. Sales increased 9% year over year to 15.14 billion Swiss francs (~$17.5 billion). The company’s pharmaceuticals division reported sales of 11.
Roche comes out against clearing takeover of drug manufacturer Catalent
The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by Novo Nordisk's controlling shareholder, citing harm to industry peers.
Roche CEO says antitrust regulators should block Catalent sale to Novo Foundation
The CEO of Swiss pharmaceuticals behemoth Roche (OTCQX:RHHBY) said he believes antitrust regulators should not allow Novo Nordisk Foundation's to purchase Catalent (NYSE:CTLT). "It's not a problem for us,
BioSpace
2d
Why It’s OK to Talk About Catalent’s Pending Buyout by ‘Novo’
The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of ...
STAT
5d
Catalent tries to reassure customers about its deal with Novo Holdings
Catalent, a leading contract drug manufacturer, issued an open letter Monday to reassure customers that a proposed $16.5 ...
5d
Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings
Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, ...
Zacks.com on MSN
10d
Catalent Stock Flat Following the Sell Agreement With Ardena
Catalent CTLT recently announced that it has entered into a definitive agreement to sell its oral solids development and ...
5d
on MSN
Catalent CEO to Remain in Charge of Contract Drugmaker After Novo Holdings' Buyout
(Reuters) - Catalent CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker ...
bovnews
3d
The Catalent Inc Stock Thriller: Decoding the Mystery Behind CTLT’s Recent Movements
On Tuesday, Catalent Inc (CTLT) stock saw a decline, ending the day at $59.92 which represents a decrease of $-0.26 or -0.43% from the prior close of $60.18. The stock opened at $60.14 and touched a ...
FiercePharma
12d
Catalent offloads New Jersey manufacturing plant, HQ to Belgian CDMO Ardena
Awaiting a potential acquisition by Novo Holdings, Catalent is giving its contract manufacturing compatriot a boost as Ardena ...
STAT
5d
Pharmalittle: We’re reading about ballooning 340B drug sales, Catalent reassuring customers, and more
Confounding data from a Pfizer clinical trial have rattled the field of gene therapy for Duchenne muscular dystrophy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Roche
Eli Lilly and Company
Novo Holdings
CTLT
Feedback